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Recent studies have demonstrated that the membrane-proximal external region (MPER) of human immunodeficiency virus 1 
(HIV-1) glycoprotein 41 contains a series of epitopes for human monoclonal antibodies, including 2F5, Z13e1, 4E10, and 
10E8, which were isolated from HIV-1-infected individuals and show broad neutralizing activities. This suggests that MPER is 
a good target for the development of effective HIV-1 vaccines. However, many studies have shown that it is difficult to induce 
antibodies with similar broad neutralizing activities using MPER-based peptide antigens. Here, we report that 10E8-like neu-
tralizing antibodies with effective anti-HIV-1 activity were readily induced using a precisely designed conformational immu-
nogenic peptide containing the 10E8-specific epitope. This immunogenic peptide (designated T10HE) contains a 15-mer 
MPER-derived 10E8-specific epitope fused to T-helper-cell epitopes from tetanus toxin (tt), which showed a significantly sta-
bilized -helix structure after a series of modifications, including substitution with an (S)--(2-pentenyl) alanine containing an 
olefin-bearing tether and ruthenium-catalyzed olefin metathesis, compared with the unmodified T10E peptide. The stabilized 
-helix structure of T10HE did not affect its capacity to bind the 10E8 antibody, as evaluated with an enzyme linked immuno-
sorbent assay (ELISA) and surface plasmon resonance binding assay (SPR assay). The efficacies of the T10HE and T10E 
epitope vaccines were evaluated after a standard vaccination procedure in which the experimental mice were primed with ei-
ther the T10HE or T10E immunogen and boosted with HIV-1 JRFL pseudoviruses. Higher titers of 10E8-like antibodies were 
induced by T10HE than that by T10E. More importantly, the antibodies induced by T10HE showed enhanced antiviral potency 
against HIV-1 strains with both X4 and R5 tropism and a greater degree of broad neutralizing activity than the antibodies in-
duced by T10E. These results indicate that a 10E8-epitope-based structure-specific peptide immunogen can elicit neutralizing 
antibodies when used as a vaccine prime. 
MPER, peptide immunogen, vaccine prime, neutralizing antibody 
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Until now, no effective vaccine that can induce broad neu-
tralizing antibodies for human immunodeficiency virus 
(HIV) has been developed because its envelope glycopro-
teins (Envs) are highly mutable and carry massive glycans 
[1]. Although most of the antibodies induced in natural 
HIV-1 infections in humans are often quite strain-specific or 
even completely nonneutralizing, it is now evident that 
10%–25% of infected individuals could eventually induce 
broad neutralizing antibodies (BNAbs) [2]. In recent years, 
a few of these BNAbs have been isolated from such indi-
viduals using state-of-the-art single-B-cell-based sorting 
and antibody cDNA cloning technology [39]. Four such 
BNAbs, 2F5, 4E10, Z13e1, and 10E8, bind to continuous 
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epitopes on the membrane-proximal external region (MPER) 
of HIV-1 glycoprotein 41 (gp41) [1012]. 
MPER is conserved among all HIV-1 subtypes [13,14]. 
The cocrystallization of MPER with these antibodies pro-
vides valuable information for the design of vaccination 
strategies. The structure of the 2F5 epitope displays differ-
ent forms in the presence or absence of 2F5 BNAb, showing 
a kinked extended structure [15] or a 310 helix, respectively 
[16,17]. The structure of MPER contains two helices when 
it is complexed with the antigen-binding fragment (Fab) of 
10E8. The important residues of MPER that bind to the 
10E8 BNAb are Trp672, Phe673, Trp680, and Lys/Arg683 
[12], which show a typical conformational epitope structure. 
10E8 is a BNAb newly identified in 2012, which amazingly 
neutralized ~98% of the 180 viruses tested at an IC50<50 µg 
mL1, so it is very likely that the 10E8 epitope on MPER is 
an excellent candidate epitope for the development of an 
effective HIV-1 vaccine. However, there has been little re-
search in this area, so in this study, we used a 10E8-epitope- 
based immunogen as the bait to elicit 10E8-like antibodies. 
Like anti-HIV drugs that are specific to conformational tar-
gets [18], epitope-based vaccine constructs must also be 
designed precisely according to the epitopes of known 
BNAbs to elicit BNAbs-like neutralizing antibodies. For 
example, Joseph et al. [19] modified the original VRC01 
epitope on gp120 with computational assistance, and the 
new format, eOD-GT6, showed improved binding to multi-
ple VRC01-class BNAbs and their germline precursors. The 
modified immunogen eOD-GT6 can efficiently activate 
both germline and mature VRC01-class B cells, suggesting 
that a germline-targeting strategy can potentially be used to 
design a vaccine prime. In our case, although the MPER of 
gp41 contains a series of well-characterized BNAbs, in-
cluding 2F5, 4E10, Z13e1, and 10E8, it is conformationally 
flexible in the format of a synthesized peptide [20]. At-
tempts have been made to induce 2F5- and 4E10-like neu-
tralizing antibodies by conjugating the 2F5 or 4E10 epitope 
to scaffolds [20,21]. However, these have failed, partly be-
cause the scaffolds themselves are highly immunogenic, 
which inevitably causes the immune system to produce nu-
merous nonneutralizing antibodies. In this study, we gener-
ated a stabilized helical conformation of the 10E8 epitope 
by chemically modifying the original sequence of the 10E8 
epitope rather than introducing a scaffold, to avoid the pro-
duction of unwanted antibodies. 
MPER-derived peptide antigens, including the 10E8 
epitope peptide, are poorly immunogenic [22]. It is very 
important to conjugate the 10E8 epitope peptide to an ap-
propriate carrier molecule, and ideally, the carrier should 
stimulate T-helper-cell responses to efficiently induce a 
10E8-epitope-specific humoral response [23]. Current re-
search indicates that CD4+ T cells are essential for the in-
duction of effective antiviral immunity in both CD8+ T-cell 
responses and B-cell responses in vivo [24,25]. In this con-
text, the well-characterized immunogenic T-cell epitopes 
within the tetanus toxin (tt) could increase the activation of 
CD4+ T-helper cells by our 10E8-epitope-based immunogen, 
whereas trials with the whole tt protein should be avoided 
because it has a known immunosuppression function [23]. 
The immunization strategy is another crucial factor in 
vaccine studies. Recently, much attention has been directed 
toward the heterologous prime-boost strategy, which was 
shown to be effective in nonhuman primates in 1992 [26]. 
That pivotal report provided a practical approach to induc-
ing the most effective humoral immune responses to weak 
immunogens. In this study, we fully appreciated the im-
portance of the prime-boost strategy and incorporated it into 
the immunization strategy for our 10E8-epitope-derived 
vaccine construct. However, even the effects of the best 
prime-boost strategies can vary from patient to patient. 
Therefore, in this study, we also extensively explored dif-
ferent prime-boost approaches. 
In summary, here we report a 10E8-epitope-based pep-
tide vaccine construct, designated the “TT-10E8 helical 
epitope” (T10HE), consisting of a MPER-derived 10E8- 
specific 15-mer peptide fused to T-cell epitopes (tt). The 
hydrocarbon stapling method was used to stabilize the 
15-mer 10E8 epitope peptide in a rigid helical conformation. 
We then tested the hypothesis that a rigid conformation is 
suitable for using as a vaccine prime with a T10HE prime- 
pseudovirus boost strategy. 
1  Materials and methods 
1.1  Ethics statement 
All procedures for the use and care of experimental animals 
were approved by the Institutional Animal Care and Use 
Committee of Tsinghua University and the Ethics and Wel-
fare of Experimental Animals Committee of Tsinghua Uni-
versity (permit number: 13-CYH5). All experiments were 
performed according to institutional guidelines. 
1.2  Peptides, reagents, cells, and viruses 
The peptides, shown in Figure 1, were designed and synthe-
sized. MPER (RRRNEQELLELDKWASLWNWFDITN- 
WLWYIRRRR), TT peptide (FNNFTVSFWLRVPKVS- 
ASHLE), T10HE peptide (FNNFTVSFWLRVPKVSA-  
SHLE-PEG2-LWNWF-S5-ITN-S5-LWYIR-PEG2-KK),  
and T10E peptide (FNNFTVSFWLRVPKVSASHLE- 
PEG2-LWNWFDITNWLWYIR-PEG2-KK) were pur-
chased from CPC Scientific Inc. (Sunnyvale, CA, USA). 
CpG-ODN 1826 (5-TCCATGACGTTCCTGACGTT-3) 
was synthesized with a backbone of nuclease-resistant 
phosphorothioate by Sangon Biological Engineering Tech-
nology Co. (Shanghai, China). The 10E8 monoclonal anti-
body used in this study was kindly provided by Dr. Huang 
JingHe (National Institutes of Health (NIH)). Freund’s ad-
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Figure 1  Design and sequences of the synthesized peptide immunogen. A, Schematic representation of the synthesized peptide T10HE with an enhanced 
-helix. TT, tetanus toxoid (residues 947–967); i and i+4, hydrocarbon-stapled sites. B, The amino acid sequences of MPER, T10HE, T10E, and TT. The 
last 15 residues of MPER are shown in red and blue. The critical residues for 10E8 binding are highlighted in blue. PEG2, flexible linker 
(–NHCH2CH2OCH2CH2OCH2CO–); S5, hydrocarbon-stapled site [(S)--(2-pentenyl) alanine]. 
juvant and incomplete Freund’s adjuvant were purchased 
from Pierce (Rockford, IL, USA). Green fluorescent protein 
(GFP)-transduced human osteosarcoma (ghost) cells ex-
pressing CD4 and coreceptors CCR5 and CXCR4 and 
plasmids pSF162-Env, pCNE3-Env, pCNE28-Env, and 
pCNE49-Env were kind gifts from Dr. Zhang LinQi of 
Tsinghua University. HEK 293T cells and plasmids 
pNL4-3.Luc.R–E–, pJRFL-Env, and pHXB2-Env were ob-
tained from the NIH AIDS Research and Reference Reagent 
Program. Anti-human IgG was purchased from Sigma (St. 
Louis, MO, USA). Anti-mouse IgG was purchased from 
Dako (Glostrup, Denmark). 
1.3  Circular dichroism (CD) analysis 
The secondary structures of the synthetic peptides were de-
termined with CD spectroscopy, as described previously 
[27,28]. Briefly, the individual peptides were prepared in 
phosphate-buffered saline (PBS) containing 50% trifluoro-
ethanol (TFE) at a final concentration of 10 mmol L1. Data 
were obtained on an Applied Photophysics Pi-Star 180 
spectropolarimeter (Surrey, UK) with predetermined pa-
rameters (3 nm bandwidth, 0.1 nm resolution, 0.1 cm path 
length, 1 nm wavelength interval from 200 to 260 nm) and 
corrected by the subtraction of the background solvent. The 
-helix content was calculated from the CD signal by di-
viding the mean residue ellipticity at 222 nm. 
1.4  SPR assay 
The binding of synthesized peptides T10HE, T10E, and 
MPER to 10E8 was assayed with a Biacore T200 instru-
ment, as previously described [29,30]. Briefly, full-length 
10E8 antibody (IgG) was captured on a CM5 chip (Uppsala, 
Sweden), according to standard amine coupling procedures, 
including the activation of L2 with a fresh mixture of  
0.2 mol L1 ethyl (dimethylaminopropyl) carbodiimide and 
0.05 mol L1 N-hydroxysuccinimide (NHS) for 7 min and 
capturing 50 g mL1 10E8 in 10 mmol L1 sodium acetate 
(pH 5.5) to the desired level (3000 RU). Ethanolamine was 
then used to block the residual reactive esters. L1 was used 
as a reference surface, without any modification. The syn-
thesized peptides T10H, T10E, and MPER were prepared as 
2-fold serial dilutions (from 500 to 31.25 nmol L1 in HBS 
running buffer: 100 mmol L1 HEPES (pH 7.4), 150 mmol 
L1 NaCl, 3.4 mmol L1 EDTA, 0.01% Tween 20). Each 
peptide was injected from low to high concentrations in a 
single-cycle mode for 100 s at the flow rate of 30 L min1, 
followed by a dissociation time of 180 s. The surfaces were 
regenerated with the injection of 5 L of 15 mmol L1 
NaOH. The data were analyzed with BiaEvalution 4.1. 
1.5  Purification of pseudoviruses 
Pseudoviruses were prepared as previously described [31]. 
In brief, HEK 293T cells were cotransfected with 
pNL4-3.LucR–E– and pJRFL-Env. After 24 h, the culture 
medium was changed to fresh Dulbecco’s modified Eagle’s 
medium. The supernatant containing the pseudoviruses was 
harvested after another 24 h and the pseudoviruses were 
purified with Lentivirus purification mini kit (San Diego, 
CA, USA), according to the manufacturer’s instructions. 
The purified pseudoviruses were dialyzed against PBS and 
stored as aliquots at −80°C. The titers of the pseudoviruses 
were determined by ELISA for p24. 
1.6  Immunization 
Twelve eight-week-old female BALB/c mice were assigned 
to three groups (four mice per group), designated groups A, 
B and C. Group A mice were primed with the T10HE pep- 
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tide and boosted with JRFL pseudoviruses. Group B mice 
were immunized with the T10E peptide and boosted with 
JRFL pseudoviruses. Group C mice were immunized with 
JRFL pseudoviruses. The peptides (20 g per mouse) were 
mixed thoroughly with Freund’s adjuvant for the first im-
munization and with incomplete Freund’s adjuvant thereaf-
ter, and injected intraperitoneally. JRFL pseudoviruses   
(1 g per mouse) were mixed thoroughly with CpG-ODN 
1826 and injected intraperitoneally. The second immuniza-
tion was given three weeks after the primary immunization, 
and two boost immunizations were given at intervals of two 
weeks thereafter. Preimmunization blood samples were col-
lected before the primary immunization. Blood samples 
were also harvested a week after each boost immunization 
and the sera were stored at −20°C. 
1.7  ELISAs 
The T10HE, T10E, and MPER peptides were coated onto 
microtiter plates (5 g mL1 in PBS (pH 7.2), 50 L/well) at 
37°C for 2 h, and blocked with 2% nonfat milk (200 
L/well in PBS) at 4°C overnight. Serially diluted primary 
10E8 antibody or mouse serum (50 L/well) was then add-
ed and the samples incubated for 2 h. A peroxidase-conju- 
gated secondary antibody, anti-human IgG or anti-mouse 
IgG, was added to the sera and incubated for 1 h at room 
temperature. The freshly prepared ortho-phenylenediamine 
(OPD) solution (10 mg OPD in 10 mL of 0.1 mol L1 citrate 
buffer (pH 5.0), 20 L H2O2) was added (50 L/well). After 
10 min, the reaction was stopped with 2 mol L1 H2SO4. 
Data were obtained at an optical density of 490 nm (A490) on 
a Bio-Rad Model 680 (Hercules, CA, USA). 
1.8  HIV-1 neutralization assays 
A single-cycle pseudovirus infection assay was performed 
as previously described [27]. Briefly, pseudoviruses were 
obtained as described above. The titers of the pseudoviruses 
were determined with a 4-fold serial dilution (starting from 
1:5) in 1105 ghost cell/well, which were prepared 24 h 
before infection in a final volume of 200 L. The samples 
(50 L/well) and pseudoviruses (50 L/well) were incubat-
ed at 37°C for 1 h, and then added to the ghost cells    
(100 L/well). The cells were cultured at 37°C under 5% 
CO2. After 48 h, the cells were lysed and the relative lumi-
nescence units (RLU) detected with a luciferase kit 
(Promega, Madison, WI, USA) and a luminometer (Ultra 
386, Tecan, Durham, NC, USA). 
Mouse antisera lacking 10E8-like antibodies were pre-
pared using T10HE-conjugated microbeads, after 1 mg of 
T10HE was coupled to NHS-activated Sepharose 4 Fast 
Flow beads (GE Healthcare, Sweden), according to the 
manufacturer’s instructions. The antisera were incubated 
with the microbeads for 45 min, the mixture was centri-
fuged at 1500g for 5 min, the supernatant was collected 
and the complement was inactivated at 56°C for 30 min. 
2  Results 
2.1  Design and characterization of the helical immu-
nogen T10HE 
A series of BNAbs isolated from HIV-1-infected individu-
als showed strong binding capacity to MPER, suggesting 
that MPER is a good candidate epitope for the development 
of an HIV-1 vaccine. However, MPER is a poor immuno-
gen. To enhance the immunogenicity of the MPER-derived 
10E8 epitope peptide, we introduced universally immuno-
genic T-helper-cell 21-mer epitopes (TT) derived from the tt 
to the N-terminus of MPER. TT contains three epitopes that 
can be recognized when associated with different MHC II 
molecules [32]. We also added a flexible, low-molecular- 
weight polyethylene glycol linker (PEG2) between the 
T-cell epitope and MPER to avoid disturbing the structure 
of MPER. In an effort to form a stabilized -helical con-
formation, we substituted aspartic acid and tryptophan (at 
positions 674 and 678, respectively) with (S)--(2-pentenyl) 
alanine containing olefin-bearing tethers, followed by ruthe-
nium-catalyzed olefin metathesis (Figure 1A). The substitu-
tion positions (i and i+4) were carefully selected to avoid 
the disruption of the critical binding interface between 
MPER and 10E8, as determined from the crystal structure 
of MPER complexed with the 10E8 Fab [12]. This peptide, 
with a stabilized helical conformation, was designated the 
TT-10E8 helical peptide (T10HE for short). We also syn-
thesized a linear analogue, the TT-10E8 peptide, without 
these modifications (T10E for short) as the control (Figure 
1B). 
To assess the helicity of T10HE and T10E, a CD analysis 
was performed at 25°C in 20 mmol L1 PBS (pH 7.2) con-
taining 50% TFE. TFE is a strongly helix-promoting solvent 
for peptides [33,34]; 50% TFE was used to assay the con-
formational structure and to increase the solubility of the 
peptides. As shown in Figure 2, the spectra of T10HE and 
T10E displayed distinct secondary structures. Two negative 
bands were observed at approximately 208 and 222 nm, 
suggesting the presence of -helix. T10HE showed signifi-
cant absorption at 208 nm and weak absorption at 222 nm, 
whereas T10E showed much weaker absorption at 208 nm 
than T10HE. These results indicate that the introduction of a 
hydrocarbon bridge increases the helicity of the T10HE 
immunogen. 
2.2  Binding of 10E8 BNAb to T10HE 
Next, we tested whether the stabilized helical conformation 
within T10HE affects its recognition by 10E8 BNAb. We 
detected the binding of 10E8 to T10HE with ELISA and 
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Figure 2  T10HE peptide immunogen has a more-stabilized -helix 
structure than T10E. The secondary structures (-helices) of peptides 
T10HE and T10E were determined with CD spectroscopy. The preparation 
of the samples is described in detail in Materials and methods. One repre-
sentative result from at least two independent measurements is shown. 
SPR assay. As expected, 10E8 bound very well to T10HE 
(Figure 3), and the binding affinities for 10E8 of the three 
synthesized peptides derived from MPER were in the same 
order of magnitude (77 nmol L1 for T10E, 61.6 nmol L1 
for T10HE, and 33.9 nmol L1 for MPER, respectively) 
when quantified with the SPR assay (Figure 4). By contrast, 
the TT peptide, used as the control, was not recognized by 
10E8 (Figure 3). These results indicate that the peptide 
T10HE, with a stabilized helical conformation, maintained 
the conformational structure of the epitope, which was rec-
ognized by 10E8 BNAb. 
2.3  Inducing 10E8-like antibody responses with the 
T10HE prime-JRFL pseudovirus boost strategy 
Several studies have demonstrated that it is very difficult to  
induce antibodies with broad neutralizing activities using 
MPER-derived peptide antigens. A prime-and-boost-based 
immunization strategy has been proven to be an effective 
approach to inducing the best humoral immune responses to 
poor immunogens. However, the effects of even the best 
prime-boost strategies can vary from patient to patient. 
Therefore, we also tried different prime-boost immunization 
procedures (Figure 5A). Specifically, in group A, we used 
the T10HE prime-JRFL pseudovirus boost strategy to im-
prove the immunogenicity of the 10E8 epitope (Figure 5A, 
group A). The critical point in this immunization strategy is 
that the T10HE peptide was used for the primary immuniza-
tion (T10HE peptide as the vaccine prime) and the HIV-1 
JRFL pseudovirus was used as the boost. Group B (T10E 
peptide as the vaccine prime) and C (pseudovirus as the 
vaccine prime) were used as controls. 
 
 
Figure 3  Modified T10HE peptide antigen is recognized by 10E8 BNAb. 
The binding capacities to 10E8 BNAb of a series of synthesized epitope 
peptide antigens, T10HE, T10E, and MPER, were assessed with an ELISA. 
TT was used as the control. Means with error bars of at least two inde-
pendent experiments are shown.
 
 
Figure 4  Single-cycle kinetic analysis of the binding of the synthesized peptides to 10E8. A–C, The 10E8 BNAb was immobilized on a CM5 chip and the 
synthesized peptides T10HE (A), T10E (B), and MPER (C) were passed over it as analytes in 2-fold serial dilutions from 31.25 to 250 nmol L1. Preparation 
of the samples is described in detail in Materials and methods. D, Binding constants were calculated by fitting the sensorgrams (A–C, black) to a 1:1 Lang-
muir model (A–C, gray). ka, association rate; kd, dissociation rate; KD, equilibrium dissociation constant. One representative result from at least two inde-
pendent measurements is shown. 
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Antisera were collected at the end of the immunization 
procedure and MPER-, T10HE-, and T10E-specific anti-
bodies were detected with ELISAs. As shown in Figure 5 
and Table 1, higher levels of MPER-, T10HE-, and T10E-  
 
 
Figure 5  Immunization schedule for BALB/C mice and the detection of antibodies in antisera from groups A, B, and C, induced with three different strate-
gies. A, T10HE, closed purple symbols; T10E, closed gray symbols; JRFL pseudoviruses, open symbols; red arrow, “post 3” and “post 4” sera were collect-
ed one week after the third and fourth immunizations, respectively. B–D, Polyclonal antibody responses against MPER (B), T10HE (C), and T10E (D), as 
assessed by the binding of the post 3 antisera. Sera collected before the immunizations were used as the controls. 
Table 1  The titers of specific antibodies of groups A, B and C assessed with the post 3 antiseraa) 
Group Prime Boost 
Mouse 
No. 
Titers of antibodies specific for 
MPER T10HE T10E TT 
A T10HE JRFL 1 1:6400 1:12800 1:12800 1:100 
   2 1:6400 1:51200 1:51200 1:100 
   3 1:6400 1:51200 1:51200 1:100 
   4 1:6400 1:51200 1:51200 1:100 
Geometric mean    1:6400 1:36204 1:36203 1:100 
B T10E JRFL 1 1:800 1:12800 1:12800 1:100 
   2 1:800 1:3200 1:3200 1:200 
   3 1:1600 1:12800 1:12800 1:200 
   4 1:1600 1:12800 1:12800 1:200 
Geometric mean    1:1131 1:9050 1:9051 1:168 
C JRFL JRFL 1 1:6400 1:12800 1:12800 1:50 
   2 1:800 1:3200 1:3200 1:50 
   3 1:1600 1:12800 1:12800 1:50 
   4 1:1600 1:3200 1:3200 1:50 
Geometric mean    1:1902 1:6400 1:6400 1:50 
a) The experiment was performed in triplicate and repeated once. The mean values from one representative experiment are presented. The immunogenic-
ity of groups AC was assessed with sera of post 3. 
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specific antibodies were efficiently induced in group A than 
in the other two control groups. Anti-HIV antibodies pre-
dominated over anti-TT antibodies. The isotypes of the 
10E8-like antibodies in these three groups were also deter-
mined. As shown in Figure 6, significantly higher levels of 
the IgG1 subtype were induced in group A (Figure 6A), and 
moderately higher levels of the IgM and IgG2a subtypes 
(Figure 6B and C) than in control groups B and C. These 
results show that the T10HE prime-JRFL pseudovirus boost 
strategy efficiently induced the 10E8-like antibody response 
with diverse immunoglobulin subtypes. 
2.4  Detection of neutralizing activity of 10E8-like an-
tibodies 
Next, we tested the antiviral activity of these 10E8-epitope- 
specific antibodies. Antisera from the three groups were 
assayed for their neutralizing activities in a pseudo-
virus-based assay system using ghost cells expressing CD4, 
CCR5, and CXCR4 as the target cells. Because JRFL pseu-
doviruses were used as the immunogen in the boost im-
munization, we first detected the neutralizing potency of 
antisera against the JRFL strain (CCR5 tropism). As ex- 
 
 
Figure 6  Determination of the 10E8-like antibody subtypes induced with different prime-boost strategies. A–F, Sera collected in the post 4 batch, shown in 
Figure 5, were assessed. Titers of anti-MPER IgG1 (A), IgM (B), IgG2a (C), IgG2b (D), IgG3 (E), and IgA (F) were measured in triplicate. Data are ex-
pressed as means and error bars. 
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pected, the antisera from group C showed moderate antivi-
ral potency, with IC50 of 1:40 (two mice) and <1:20 (two 
mice) (Table 2). Using group C antisera as the baseline, it 
was striking to see that the antisera of group A displayed 
significantly enhanced neutralizing potency, with IC50 of 
1:160 (three mice) and 1:80 (one mouse), whereas that of 
group B could not neutralize 50% of pseudoviruses at a di-
lution of 1:20. We then tested another tropic (CXCR4) 
pseudovirus, HXB2. Antisera from group A efficiently neu-
tralized HXB2 at IC50 of 1:20 (three mice) and 1:40 (one 
mouse) compared with the antisera from groups B and C. 
These results suggest that the antisera of group A exhibited 
cross-neutralization against pseudoviruses with different 
tropisms. However, the antisera from all three groups failed 
to neutralize another laboratory-adapted strain, SF162, at 
dilutions of 1:20. The SF162 pseudoviruses were resistant 
to the antisera from group A, probably because the 10E8 
epitope sequence derived from JRFL and T10HE differs 
from SF162 at position 676, where threonine occurs in 
T10HE and JRFL, but serine occurs in SF162. We then de-
tected the antisera against pseudoviruses from primary iso-
lates. As shown in Table 2, the antisera from group A neu-
tralized 50% of the CNE3, CNE28, and CNE49 strains at a 
dilution of >1:20. Although groups A and B were boosted 
with the same pseudovirus, different priming resulted in the 
induction of 10E8-like antibodies with very different neu- 
tralizing activities. Group A antisera induced cross-    
neutralizing antibodies, which showed a certain degree of 
broad neutralization activity, whereas group B antisera did 
not. These results suggest that T10HE is a potential vaccine 
prime for future vaccine designs when combined with a 
suitable boost strategy. 
2.5  Preabsorption of 10E8-like antibodies eliminated 
the neutralizing capacity of group A antisera 
Because the envelope protein of JRFL consists of gp120 
and gp41, we tested whether 10E8-like neutralizing anti-
bodies from group A played a major role in an antiviral as-
say. We preabsorbed 10E8-like antibodies from these anti-
sera to T10HE-conjugated microbeads. As shown in Table 3, 
after these antibodies were removed, the neutralization ca-
pacity of the group A antisera was eliminated. Even at a 
dilution of 1:20, they still did not neutralize four of the five 
pseudoviruses tested in our assay system. When we tested 
the CNE28 pseudovirus, it was clear that a significant re-
duction in the neutralization capacity had occurred; the un-
absorbed antisera had an IC50 of 1:160 (four mice), which 
decreased to an IC50 of 1:40 (three mice) or 1:20 (one 
mouse) with the absorbed antisera (Tables 2 and 3). These 
results indicate that the antiviral potency of group A is 
probably attributable to 10E8-like antibodies. 
Table 2  Neutralizing activity of post 4 antisera against infection by HIV-1 pseudovirusesa) 
Group Mouse No. 













A 1 1:160 1:40 <1:20 1:40 1:160 1:20 
 2 1:160 1:20 <1:20 1:40 1:160 1:40 
 3 1:160 1:20 <1:20 1:80 1:160 1:40 
 4 1:80 1:20 <1:20 1:80 1:160 1:20 
B 1 <1:20 <1:20 <1:20 <1:20 1:20 <1:20 
 2 <1:20 <1:20 <1:20 <1:20 <1:20 1:20 
 3 <1:20 <1:20 <1:20 <1:20 1:40 <1:20 
 4 <1:20 <1:20 <1:20 <1:20 1:40 1:20 
C 1 <1:20 <1:20 <1:20 1:20 1:40 <1:20 
 2 1:40 <1:20 <1:20 <1:20 1:20 <1:20 
 3 1:40 <1:20 <1:20 <1:20 <1:20 <1:20 
 4 <1:20 <1:20 <1:20 1:20 1:40 <1:20 
a) The experiment was performed in triplicate and repeated at least once.  
Table 3  Neutralization titers of antisera after MPER-specific antibodies exclusiona)  
Mouse No. Titers of IC50 against HIV-1 pseudoviruses 
Group A HXB2 JRFL CNE3 CNE28 CNE49 
1 <1:20 <1:20 <1:20 1:40 <1:20 
2 <1:20 <1:20 <1:20 1:40 <1:20 
3 <1:20 <1:20 <1:20 1:20 <1:20 
4 <1:20 <1:20 <1:20 1:40 <1:20 
a) The experiment was performed in triplicate and repeated at least once.  
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3  Discussion 
Because MPER is immunorecessive [31,35] and shows a 
variety of transient conformations in its native microenvi-
ronment [11,15,36,37], the induction of MPER-specific 
neutralizing antibodies has been very challenging until now. 
Considerable efforts have been made to induce BNAbs by 
designing MPER-containing immunogens in the context of 
various scaffolds, including hepatitis B surface antigen [38], 
computationally selected scaffolds [20], and gp120 [21]. 
However, none of these scaffold-based immunogens suc-
cessfully elicited BNAbs that target MPER-like 2F5, 4E10, 
or Z13e1. In previous studies, we reported using appropriate 
scaffolds to support MPER-containing peptides, creating a 
stabilized format for the 2F5-binding conformation or an 
-helix 4E10-binding conformation [31]. Although the an-
ti-MPER antibody titers were improved when these newly 
designed MPER-containing scaffolds were used as immu-
nogens, most of the induced antibodies were directed 
against the scaffolds, suggesting that the high immunogen-
icity of the scaffolds inevitably caused the immune system 
to produce numerous nonneutralizing and thus useless anti-
bodies. However, short neutralizing epitope-based peptides 
are rarely used as immunogens because their immunogenic-
ity is poor, and indeed, most of these short peptides must be 
conjugated to large carriers or scaffold proteins, such as 
bovine serum albumin or keyhole limpet hemocyanin, to act 
as vaccines [23]. In this study, we tried to resolve this di-
lemma by generating a stabilized helix conformation within 
a MPER-derived peptide by chemically modifying the orig-
inal sequence instead of introducing a scaffold to avoid un-
wanted nonneutralizing antibodies. Using the epitope on 
MPER that is recognized by the recently identified BNAb 
10E8, we synthesized the peptide T10HE, which contains 
an -helix structure and clearly exposes the predefined 
binding surface for BNAb10E8. Our CD analysis indicated 
that this strategy worked well and that the introduction of a 
hydrocarbon bridge increased the helicity of the T10HE 
immunogen. These results show that the T10HE peptide, 
with a rigid helical conformation, possesses the structural 
basis or potential to induce 10E8-like antibodies. When 
T10HE was used as the prime immunogen and JRFL pseu-
doviruses as the boost immunogen, the immunized mice 
produced more neutralizing antibodies than those immun-
ized with pseudoviruses alone and those primed with pep-
tide T10E, which has a nonrigid conformation. Although the 
sequence of MPER is conserved among the viruses tested, 
especially the critical binding sites (W672, F673, T/S676, 
L679, W680, and R/K683), there are slight variations in the 
sequence. We found that the last 15-mer sequence of MPER 
in the CNE3 and CNE28 strains, which are identical, dif-
fered in their sensitivity to the serum from group A. CNE49 
and HXB2 differ at two residues but showed similar sensi-
tivity. However, SF162, which differs in only one residue 
from JRFL, was resistant to the antisera. Therefore, we 
speculate that viral sensitivity to neutralization by the 
10E8-like antibody may only be partly related to sequence 
variations in MPER. We determined the neutralizing capac-
ity of the sera only after the fourth immunization, which 
suggests that this capacity is dose and time dependent. The 
increased neutralization with increasing time was partly 
attributable to the increased antibody titers [31,39]. We col-
lected the mouse sera after the third and fourth immuniza-
tions, and the titers after the fourth immunization were 
higher than those after the third immunization. Neutraliza-
tion was partly attributable to the antibody maturation and 
enhanced binding affinity for the immunogens [12,19]. In 
this study, we also determined the avidity index [40] of the 
three groups, and found that the 10E8-like antibodies from 
the sera of group A showed significantly enhanced avidity 
(P<0.05) over those of groups B and C (Figure S1 in Sup-
porting Information). The isotypes of the 10E8-like anti-
bodies of these three groups were also determined. The en-
hanced levels of IgG1, IgM, and IgG2a in group A and their 
increased avidities could also have contributed to the broad 
neutralizing activities of the 10E8-like antibodies induced. 
One possible explanation of this increased antiviral activity 
is that T10HE mimics the native conformation of the 10E8 
epitope and may bind to naïve B cells, resulting in the en-
richment of these cells in the blood circulation. The native 
immunogens expressed on the pseudoviruses or viral parti-
cles may stimulate these B cells to differentiate rapidly, 
becoming high-affinity antibody-secreting cells and pro-
ducing potent and broadly neutralizing antibodies. When all 
these data are considered together, they indicate that T10HE 
is an effective vaccine prime, at least in this research con-
text. Whether the use of immunizing peptides as vaccine 
primes could be a universal strategy requires future confir-
mation. 
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Supporting Information 
Figure S1  Avidity index of MPER-specific serum IgG (post 4) measured by chaotropic ELISA using NH4SCN. * indicates the significant difference in 
IC50 values between groups A, B and C (two tailed T test; P<0.05; n=4). The avidity index was detected by diluting sera to a concentration that corresponds 
to A490=1.0 in an endpoint ELISA, and reacting with antigen which coated to plates for 2 h at 37°C. After washing, serial dilutions of NH4SCN (463 mmol 
L1) were added. The plates were washed after 20 min, and the remaining antibodies were detected. The avidity index is the concentration of NH4SCN re-
quired to reduce the optical density (A) by 50% compared to that in wells with no NH4SCN. 
The supporting information is available online at life.scichina.com and link.springer.com. The supporting materials are 
published as submitted, without typesetting or editing. The responsibility for scientific accuracy and content remains entirely 
with the authors. 
 
